Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 12/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.41 |
| ▸ | PGR | P06401 | 6/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440605 | 0.94 | SLC6A2 (0.47) | SLC6A2SLC6A4CYP2D6SLC6A3KCNH2 | |
| SCHEMBL4687364 | 0.87 | PGR (0.43) | SLC6A2SLC6A4CYP2D6CYP2C9PGR | |
| SCHEMBL4491414 | 0.83 | CYP2D6 (0.50) | SLC6A2SLC6A4CYP2D6CYP2C9PGR | |
| SCHEMBL4491408 | 0.83 | CYP2D6 (0.50) | SLC6A2SLC6A4CYP2D6CYP2C9PGR | |
| SCHEMBL4485140 | 0.83 | CYP2D6 (0.50) | SLC6A2SLC6A4CYP2D6CYP2C9PGR | |
| SCHEMBL4485135 | 0.83 | CYP2D6 (0.50) | SLC6A2SLC6A4CYP2D6CYP2C9PGR | |
| SCHEMBL5112323 | 0.82 | SLC6A2 (0.41) | SLC6A2SLC6A4CYP2D6CYP2C9PGR | |
| SCHEMBL4497702 | 0.80 | SLC6A2 (0.60) | SLC6A2SLC6A4CYP2D6CYP2C9PGR | |
| SCHEMBL4687367 | 0.79 | SLC6A2 (0.43) | SLC6A2SLC6A4CYP2D6SLC6A3KCNH2 | |
| SCHEMBL5112330 | 0.78 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7619096-B2 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY (US) | 2009-11-17 | — | — | US | disclosed |
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | ELI LILLY AND COMPANY | 2006-11-30 | — | — | US | disclosed |
| EP-1638934-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000811-A1 | 3-AMINOPYRROLIDINES AS INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270713-A1 | 3-Aminopyrrolidines as inhibitors of monoamine uptake | SLC6A2, SLC6A3, SLC18A2 | SLC6A2 1/4885SLC6A4 5/4885CYP2D6 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.